CD4 and breast carcinoma: It has been demonstrated previously that CD4–CD161++Vα7.2+ MAIT cells have a superior ability to survive anthracycline‐containing chemotherapy in patients undergoing treatment for breast cancer compared to other T cell subsets [17].